Works by Bekaii-Saab, T

Results: 8

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.

Published in:

British Journal of Cancer, 2015, v. 113, n. 2, p. 220, doi. 10.1038/bjc.2015.197

By:

Wu, C;
Mikhail, S;
Wei, L;
Timmers, C;
Tahiri, S;
Neal, A;
Walker, J;
El-Dika, S;
Blazer, M;
Rock, J;
Clark, D J;
Yang, X;
Chen, J L;
Liu, J;
Knopp, M V;
Bekaii-Saab, T

Publication type:

Article

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.

Published in:

British Journal of Cancer, 2012, v. 106, n. 10, p. 1583, doi. 10.1038/bjc.2012.144

By:

Prado, C M M;
Bekaii-Saab, T;
Doyle, L A;
Shrestha, S;
Ghosh, S;
Baracos, V E;
Sawyer, M B

Publication type:

Article

Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.

Published in:

Medical Oncology, 2016, v. 33, n. 4, p. 1, doi. 10.1007/s12032-016-0753-9

By:

Bupathi, M.;
Ahn, D.;
Wu, C.;
Ciombor, K.;
Stephens, J.;
Reardon, J.;
Goldstein, D.;
Bekaii-Saab, T.

Publication type:

Article

A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.

Published in:

2010

By:

Ramaswamy B;
Bekaii-Saab T;
Schaaf LJ;
Lesinski GB;
Lucas DM;
Young DC;
Ruppert AS;
Byrd JC;
Culler K;
Wilkins D;
Wright JJ;
Grever MR;
Shapiro CL;
Ramaswamy, Bhuvaneswari;
Bekaii-Saab, Tanios;
Schaaf, Larry J;
Lesinski, Gregory B;
Lucas, David M;
Young, Donn C;
Ruppert, Amy S

Publication type:

journal article

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study.

Published in:

2022

By:

Uson Jr., P. L. S.;
Kunze, K. L.;
Golafshar, M. A.;
Botrus, G.;
Riegert-Johnson, D.;
Boardman, L.;
Borad, M. J.;
Ahn, D.;
Sonbol, M. B.;
Kahn, A.;
Klint, M.;
Esplin, E. D.;
Nussbaum, R. L.;
Stewart, A. K.;
Bekaii-Saab, T.;
Samadder, N. J.;
Uson, P L S Jr

Publication type:

journal article

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Published in:

2013

By:

Bauer TM;
El-Rayes BF;
Li X;
Hammad N;
Philip PA;
Shields AF;
Zalupski MM;
Bekaii-Saab T;
Bauer, Todd M;
El-Rayes, Bassel F;
Li, Xiaobai;
Hammad, Nazik;
Philip, Philip A;
Shields, Anthony F;
Zalupski, Mark M;
Bekaii-Saab, Tanios

Publication type:

journal article

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.

Published in:

2012

By:

Ocean AJ;
Pennington KL;
Guarino MJ;
Sheikh A;
Bekaii-Saab T;
Serafini AN;
Lee D;
Sung MW;
Gulec SA;
Goldsmith SJ;
Manzone T;
Holt M;
O'Neil BH;
Hall N;
Montero AJ;
Kauh J;
Gold DV;
Horne H;
Wegener WA;
Goldenberg DM

Publication type:

journal article

Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis.

Published in:

Internal Medicine Journal, 2008, v. 38, n. 4, p. 281, doi. 10.1111/j.1445-5994.2008.01646.x

By:

Kapoor, K. G.;
Bekaii-Saab, T.

Publication type:

Article